77.35
1.87%
+1.42
Axsome Therapeutics Inc (AXSM) 最新ニュース
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Zacks Investment Research
First Turn Management LLC Acquires Shares of 295,428 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
MarketBeat
Axsome: 1Q Earnings Snapshot - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options - Yahoo News UK
Yahoo News UK
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options - Yahoo Movies UK
Yahoo Movies UK
CFO & Principal Accounting Officer Nick Pizzie Just Bought Shares In Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Yahoo Canada Shine On
Yahoo Canada Shine On
21,086 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Truist Financial Corp - MarketBeat
MarketBeat
Prediction: These 2 Growth Stocks Could Triple By 2030
The Motley Fool
Truist Financial Corp Takes $1.68 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
Defense World
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasted to Earn Q2 2024 Earnings of ($1.31) Per Share - Defense World
Defense World
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $121.92 Consensus PT from Brokerages - MarketBeat
MarketBeat
HC Wainwright Analysts Cut Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
Defense World
Why Axsome Therapeutics Stock Is A Promising Stock Pick In CNS Treatments (NASDAQ:AXSM) - Seeking Alpha
Seeking Alpha
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Defense World
Equities Analysts Set Expectations for Axsome Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:AXSM) - Defense World
Defense World
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Expected to Post Q2 2024 Earnings of ($1.35) Per Share - Defense World
Defense World
Research Analysts Offer Predictions for Axsome Therapeutics, Inc.'s Q3 2025 Earnings (NASDAQ:AXSM) - MarketBeat
MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Yahoo Finance
Research Analysts Issue Forecasts for Axsome Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:AXSM) - Defense World
Defense World
Axsome Therapeutics (NASDAQ:AXSM) Given New $106.00 Price Target at Mizuho - MarketBeat
MarketBeat
Axsome Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
GlobeNewswire
Axsome Therapeutics (NASDAQ:AXSM) Price Target Increased to $112.00 by Analysts at Robert W. Baird - Defense World
Defense World
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates - Yahoo Canada Finance
Yahoo Canada Finance
Axsome Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Simply Wall St
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates - Yahoo Finance
Yahoo Finance
Earnings call: Axsome Therapeutics sees robust growth in Q1 2024 - Investing.com
Investing.com
Earnings call: Axsome Therapeutics sees robust growth in Q1 2024 - Investing.com
Investing.com
Axsome: Q1 Earnings Snapshot - Houston Chronicle
Houston Chronicle
Axsome: Q1 Earnings Snapshot - Darien Times
Darien Times
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
The Motley Fool
Axsome Therapeutics Inc earnings missed by $0.22, revenue topped estimates - Investing.com South Africa
Investing.com South Africa
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
GlobeNewswire
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - The Bakersfield Californian
The Bakersfield Californian
Axsome: Q1 Earnings Snapshot - Milford Mirror
Milford Mirror
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings? - MSN
MSN
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
Zacks Investment Research
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings? - Zacks Investment Research
Zacks Investment Research
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
Cannell & Co. Decreases Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
MarketBeat
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks Investment Research
Axsome Therapeutics Recognizes May as Mental Health Awareness Month - GlobeNewswire
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term ... - GlobeNewswire
GlobeNewswire
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition - InvestorPlace
InvestorPlace
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
Benzinga
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Zacks Investment Research
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Up to $71.71 - MarketBeat
MarketBeat
Axsome Therapeutics, Inc. to Post Q1 2024 Earnings of ($1.26) Per Share, William Blair Forecasts (NASDAQ:AXSM) - Defense World
Defense World
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term ... - GlobeNewswire
GlobeNewswire
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
The Motley Fool
大文字化:
|
ボリューム (24 時間):